Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (LB-04-THAL)

March 13, 2013 updated by: Boston University

An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia

Beta thalassemia intermedia syndromes are genetic anemias caused by mutations which reduce production of beta globin, a major component of adult hemoglobin A, the protein which delivers oxygen throughout the body. Patients suffer from poor growth, fatigue, heart failure, endocrine deficiencies, and eventually, many require chronic blood transfusions. There is no approved therapeutic for the deficiency of beta globin chains in beta thalassemia.

This trial will study an oral therapeutic which stimulates production of fetal globin, an alternate type which is produced by all humans, but is normally switched off in infancy. This type of globin can compensate for the missing protein in beta thalassemia.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This is a trial of an experimental oral medicine which stimulates production of fetal hemoglobin, an innate type of hemoglobin which is normally made but is suppressed in infancy. Fetal globin (HbF) can perform the function of the missing beta globin and reduce anemia in beta thalassemia, when it is produced in higher amounts than normal.

In this trial, 10 patients with beta thalassemia intermedia in Lebanon will all receive the study drug for 6 months at a dose which has been previously shown to be safe in normal volunteers and in beta thalassemia and sickle cell patients and to stimulate fetal globin production in many, when given for brief periods. The purpose of this trial is the following:

  1. To determine if total hemoglobin levels increase above baseline in some subjects when the study drug is taken for 26 weeks.
  2. To determine if fetal globin is increased above baseline levels in a proportion of subjects when the study drug is taken for 26 weeks.
  3. To determine the number of adverse events which occur with 26 weeks of administration of the study drug in beta thalassemia intermedia subjects.

After a screening period, the subjects will take the study drug at home once a day. They will be seen once every 4 weeks for examinations and laboratory tests during the dosing period and for 4 weeks afterwards.

This trial will provide an important step in evaluating a potential treatment for patients with beta thalassemia intermedia, that can be used around the world, if it is effective and safe.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beirut, Lebanon
        • Chronic Care Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of beta thalassemia intermedia
  • Ages 16-50 years
  • Average total Hgb levels between 6.0 and 9.0 gm/dl within 30 days of initial dose of study drug
  • Able to comply with all study procedures
  • If female and of childbearing potential, must have a documented negative pregnancy test prior to entry and every 4 weeks

Exclusion Criteria:

  • Red blood cell transfusions within 3 months prior to administration of study drug
  • QT Segment corrected (QTc)> 450 msec
  • Use of Erythropoiesis Stimulating Agents(ESAs)within 9 days of first dose
  • Hydroxyurea treatment within 6 months of first study drug
  • History of significant arrythmias, syncope, or resuscitation
  • Alanine Transaminase (ALT)> 4x upper limit of normal
  • Serum creatinine > 1.5 mg/dl
  • Sse of iron chelating agents within 7 days of first dose
  • Pulmonary hypertension requiring oxygen therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sodium 2,2 dimethylbutyrate
A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
Other Names:
  • ST20

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To measure changes from baseline in total hemoglobin when HQK-1001 is administered orally for 26 weeks in subjects with beta thalassemia intermedia.
Time Frame: 6 months
Baseline hemoglobin levels will be determined in each subject and averaged from levels obtained on a screening visit and on day one of the study, before any drug is taken. Hemoglobin levels will then be analyzed every 4 weeks during 26 weeks of taking the study drug and for 4 weeks after the dosing is completed. Changes from baseline will be determined.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To measure the number of adverse events which occur with HQK-1001 treatment when given over 26 weeks in beta thalassemia intermedia.
Time Frame: 6 months
Adverse events which occur during HQK-1001 administration for 26 weeks will be recorded every 4 weeks.
6 months
To measure changes from baseline in HbF during treatment with HQK-1001 for 26 weeks in beta thalassemia intermedia.
Time Frame: 6 months
Levels of HbF will be averaged from a screening visit and day 1 of the study, prior to any drug treatment. HbF levels will then be measured every 4 weeks during treatment and for 4 weeks after the treatment, and compared to each subject's baseline value. The number of subjects in which an increase in HbF develops above individuals' average baseline value will be obtained.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Susan P Perrine, MD, Boston University
  • Principal Investigator: Adlette Inati, MD, Chronic Care Center and Rafik Hariri University Hospital, Beirut, Lebanon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2012

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

January 1, 2013

Study Registration Dates

First Submitted

July 12, 2012

First Submitted That Met QC Criteria

July 16, 2012

First Posted (Estimate)

July 17, 2012

Study Record Updates

Last Update Posted (Estimate)

March 14, 2013

Last Update Submitted That Met QC Criteria

March 13, 2013

Last Verified

March 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Beta Thalassemia Intermedia

Clinical Trials on Sodium 2,2 dimethylbutyrate

3
Subscribe